Head-to-head evidence
BPL-003 (mebufotenin benzoate) vs Mebufotenin (5-MeO-DMT)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
BPL-003 (mebufotenin benzoate)
Developed by Eli Lilly and partners
NCT05870540 · Phase 2 · completed
The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT05660642 (registry estimate)
Mebufotenin (5-MeO-DMT) · GH001
Developed by GH Research
NCT05800860 · Phase 2 · completed
The study randomly assigned 81 participants and used quadruple blinding with a placebo comparator. Its primary endpoint was the change in MADRS depression scores from baseline to Day 7. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPL-003 (mebufotenin benzoate)'s landscape · Mebufotenin (5-MeO-DMT)'s landscape